Now I have all the information I need. Here is the final consolidated review.

---

## Summary

This paper proposes PIRN, a prototype-driven reconstruction framework for few-shot multimodal anomaly detection (RGB + 3D surface normals). It introduces three components: Balanced Prototype Assignment (BPA) using optimal transport to prevent codebook collapse, Adaptive Prototype Refinement (APR) that updates prototypes at test time to cover unseen normal variation, and Multimodal Normality Communication (MNC) that exchanges prototype-level normal knowledge across modalities. Experiments on MVTec-3D-AD, Eyecandies, and Real-IAD D3 show consistent gains over several baselines in few-shot settings, together with substantial computational efficiency (103G FLOPs, 17.5ms latency).

## Strengths

1. **Well-motivated architecture design.** The paper identifies three concrete failure modes of existing MAD methods in few-shot settings (codebook collapse, static codebook coverage, and lack of cross-modal communication) and designs BPA, APR, and MNC to address each one. The components are not a grab-bag — each follows coherently from the diagnosed limitation.

2. **Consistent empirical gains on two standard benchmarks.** In Table 1, PIRN outperforms all compared baselines across all shot settings on both MVTec-3D-AD and Eyecandies. The gains are largest in the lowest-shot settings (e.g., +3.9 AUROC_I on 5-shot MVTec, +4.0 on 10-shot Eyecandies), matching the paper's thesis.

3. **Substantial computational efficiency.** Table 4 reports 103G FLOPs and 17.5ms latency for PIRN vs. 728G and 76ms for FIND (the closest competitor in accuracy). This is a genuine practical advantage and the paper is honest about reporting both accuracy and efficiency.

4. **Informative ablations.** Tables 5–7 ablate prototype count, decoder depth, and APR aggregation method with interpretable trends (e.g., too many prototypes weaken the bottleneck, too many decoder layers overfit).

## Weaknesses

### Fatal
None.

### Major

1. **Most relevant SOTA baseline (FIND) is excluded from the main results table.** The paper calls FIND "recent SOTA" (Sec. 4, Computational Efficiency) and uses FIND's procedure to generate surface normal maps. Yet FIND appears only in the efficiency-focused Table 4, not in the main performance comparison (Table 1). On the single setting where a comparison is available through Table 4 (10-shot MVTec-3D-AD), PIRN achieves 0.922 vs. FIND's 0.921 — essentially a tie. The reader cannot assess how PIRN compares to FIND on 5-shot, 50-shot, or Eyecandies settings. The paper's claim of "consistently achieving superior performance" (abstract) is asserted without direct comparison to the most contemporaneous SOTA on those settings. This is an evidential gap: the conclusions may still hold, but the evidence as presented is incomplete relative to the strength of the claims made.

2. **No measure of variance or statistical significance.** Every number in every table is reported as a single point without standard deviations, confidence intervals, or even a statement about which random seeds/data splits were used. For a few-shot paper where results are known to be sensitive to which specific 5 or 10 samples are drawn, this is a significant methodological gap. Small margins (e.g., the 0.2-point gain on Eyecandies All-shot AUROC_I, or the 0.1-point margin over FIND) cannot be assessed for reliability.

### Minor

3. **APR's key assumption about diffuse anomalous assignment is asserted but not empirically validated.** The paper states that "an out-of-distribution (anomalous) patch tends to be assigned more diffusely across prototypes (i.e., with low affinity to any single prototype)" (lines 106–110), which is the basis for APR's claimed robustness to anomalies during test-time refinement. No empirical evidence (e.g., histogram of OT assignment entropy for normal vs. anomalous patches, or a synthetic example) is provided to support this claim. While the claim is plausible, the paper would be stronger with direct validation.

4. **Framing overstates the "best performance" claim on Eyecandies All-shot.** The paper states "PIRN also achieves the best performance in the full-shot setting" (Sec. 4, Main Results). This is true for AUROC_I (0.948 vs. 3D-ADNAS 0.946), but PIRN's AUPRO of 0.923 is _worse_ than 3D-ADNAS's 0.946. Since the paper claims superiority across metrics (abstract: "consistently achieves superior performance"), this discrepancy should be acknowledged and discussed.

5. **No discussion of failure cases or limitations.** On Real-IAD D3, PIRN scores only 0.604 AUROC_J on miniature_filling_sensor (Table 8), a category where D³M achieves 0.975. The paper does not discuss such failure cases or what types of anomalies/objects the method struggles with. A limitations section would improve the paper.

### Trivial
None.

## Nice-to-Haves

- **Empirically validate APR's anomaly-diffusion assumption** via entropy histograms or a synthetic toy example (related to Minor weakness 3).
- **Add a finer-grained ablation of MNC's two substages** (prototype alignment vs. cross-modal injection) to disentangle their contributions.
- **Provide guidance on choosing prototype count K** in practice, since Table 5 shows significant performance swings across K values.

## Removed Points

These points from the input review were removed with justification:

- **Table 2 component ablation appears incoherent.** All rows show identical checkmark patterns due to text-extraction corruption of the original table structure. This is a parser artifact, not an author error. **Removed per Hard Rules (formatter artifacts).**
- **Real-IAD D3 "cherry-picked" per-category comparisons.** The paper explicitly reports being second-best (AUROC_J 0.873) and explains D³M uses three modalities vs. PIRN's two. The per-category highlights are standard. The underlying concern about missing failure-case analysis is already covered by Weakness 5. **Removed.**
- **"Less than 1% of training data" is imprecise.** The figure caption clearly places this claim in the Eyecandies context. **Removed as trivial nitpick.**
- **Speculation about unreferenced 2025–2026 methods.** The reviewer suggests "there may be other 2025–2026 methods that are relevant" without naming any. **Removed per Hard Rules (speculative).**
- **Surface normal generation ablation.** A minor implementation detail; requesting it as a required comparison is scope creep. **Removed.**
- **MNC needs more detailed ablation.** A nice-to-have, not a weakness. **Moved to Nice-to-Haves.**

## Novel Insights

None beyond the paper's own contributions. The harsh critic's review identifies evidential gaps (FIND omission, lack of variance) that are real but do not introduce novel insights about the method itself beyond what is already in the paper.

## Suggestions

1. **Include FIND (and any other contemporaneous SOTA) in the main results table** so readers can directly compare performance across all shot settings. This is the single most impactful fix.
2. **Report results with variance** (mean ± std over 3–5 random few-shot splits) for at least the 5-shot and 10-shot settings. This is standard practice for few-shot work and would substantially increase confidence in the results.
3. **Empirically validate APR's diffuse-assignment claim** (e.g., a histogram of OT assignment entropy for normal vs. anomalous patches).
4. **Acknowledge the Eyecandies All-shot AUPRO gap** to 3D-ADNAS and add a limitations paragraph discussing failure cases.

## Score and Decision

**Score:** 6  
**Decision:** Borderline Accept

The paper addresses a real problem with a well-motivated, coherent architecture and demonstrates consistent gains over the baselines it includes. The computational efficiency is a genuine strength. However, the two Major weaknesses — omission of the most relevant SOTA from the main results table and complete lack of variance reporting — are evidential gaps that prevent full confidence in the claims. A revision that adds FIND to the main comparison, reports variance, and acknowledges the AUPRO discrepancy would substantially strengthen the paper.

MY FINAL SCORE: <score>6</score>
MY FINAL DECISION: <decision>Borderline Accept</decision>